Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR1137)
Name
Meropenem
Synonyms
meropenem; 96036-03-2; Merrem; Meropenem anhydrous; Meropenemum; Antibiotic SM 7338; MERONEM; SM-7338; MEPM; 119478-56-7; UNII-YOP6PX0BAO; CHEBI:43968; Meropenemum [INN-Latin]; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Meropenem (INN); Meropenem [INN]; Meropenem Hydrate; YOP6PX0BAO; Merrem I.V.; ICI-194660; (4R,5S,6S)-3-(((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4r,5s,6s)-3-{[(3s,5s)-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl}-6-[(1r)-1-Hydroxyethyl]-4-Methyl-7-Oxo-1-Azabicyclo[3.2.0]hept-2-Ene-2-Carboxylic Acid; 96036-03-2 (free); SM 7338; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; ICI 194,660; NCGC00016962-01; ICI 194660; DSSTox_CID_25526; DSSTox_RID_80930; DSSTox_GSID_45526; Meropen; (1R,5S,6S)-2-[(3S,5S)-5-DIMETHYLAMINOCARBONYLPYRROLIDIN-3-YLTHIO]-6-[(R)-1-HYDROXYETHYL]-1-METHYLCARBAPEN-2-EM-3-CARBOXYLIC ACID; (4R,5S,6S)-3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Meronem (TN); CAS-96036-03-2; MFCD08600005; Merrem I.V. (TN); SR-01000762894; HSDB 8019; Merrem IV; Meropenem,(S); M2279; BRN 6940582; PubChem17275; Meropenem (closed form); Prestwick0_001106; Prestwick1_001106; Prestwick2_001106; Prestwick3_001106; CHEMBL127; Epitope ID:195064; SCHEMBL34442; BSPBio_001212; (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; MLS001401437; BIDD:GT0851; 4-methyl-7-oxo-1-azabicyclo; SPBio_003086; BPBio1_001334; Meropenem with Sodium Carbonate; DTXSID7045526; GTPL10829; HMS1571M14; HMS2051G08; HMS2090C05; HMS2098M14; HMS3715M14; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, (4R,5S,6S)-; AMY22192; ZINC3808779; 96036-03-2 (anhydr.); Tox21_110715; Tox21_113794; BDBM50129062; AKOS015920140; Tox21_110715_1; CCG-100850; CS-1865; DB00760; KS-5224; NC00100; [3.2.0]hept-2-ene-2-carboxylic acid; NCGC00179259-01; NCGC00179259-06; NCGC00179259-17; NCGC00253670-01; NCGC00262579-02; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid; HY-13678; SMR000469184; AB0012458; AB00514051; D08185; J10087; M05727; S-3680; AB00514051-02; AB00698370-05; pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-; 036M032; Q421670; (4R,5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl); SR-01000762894-3; SR-01000762894-4; Meropenem trihydrate, Antibiotic for Culture Media Use Only; (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-[[(3S,5S)-5-(dimethylaminocarbonyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(S*,5S*),4-alpha,5-beta,6-beta(R*)))-
    Click to Show/Hide
Molecular Type
Small molecule
Disease Bacterial infection [ICD-11: 1A00-1C4Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C17H25N3O5S
PubChem CID
441130
Canonical SMILES
CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O
InChI
1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1
InChIKey
DMJNNHOOLUXYBV-PQTSNVLCSA-N
CAS Number
CAS 96036-03-2
ChEBI ID
CHEBI:43968
TTD Drug ID
D0O5FY
DrugBank ID
DB00760
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Fosfomycin      Streptomyces fradiae     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Pseudomonas aeruginosa PAO1 Microorganism model Pseudomonas aeruginosa
                    Experimental
                    Result(s)
The combination of fosfomycin plus meropenem is synergistic for pseudomonas aeruginosa PAO1 in a hollow-fiber infection model.
Target and Pathway
Target(s) Bacterial Penicillin binding protein (Bact PBP)  Molecule Info  [3]
References
Reference 1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Reference 2 The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01682-18.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China